Does More Testosterone Build More Muscle? (600mg Trial Data)

Ask around any gym and you will hear a version of the same rule: testosterone stops working somewhere around 300mg a week. Past that you get all the side effects and none of the extra muscle. It gets repeated on forums, in clinic blog posts, and by people who have run more cycles than you have.

It is not what the data says. In the only proper dose-response trial ever run on this question, fat-free mass was still climbing at 600mg a week. The curve does not bend. There is no ceiling anywhere in the tested range.

That sounds like an argument for taking more. It is not, and the reason why is more interesting than the myth.

Where the ceiling story came from

The ceiling idea has an appealing logic to it. Androgen receptors are finite, so at some point they must all be occupied, and past that extra hormone has nowhere to go. People often state this as settled science with a specific number attached.

The problem is that no human study has ever pinned a saturation point for muscle. The receptor argument is a plausible mechanism in search of evidence, and the number attached to it changes depending on who is talking. Somewhere in the retelling, "we do not know what happens above X" became "nothing happens above X".

Meanwhile the actual experiment was published in 2001 and almost nobody quotes it.

What the only real dose-response trial found

Bhasin and colleagues took 61 healthy men aged 18 to 35 and suppressed their own testosterone production with a monthly GnRH agonist. Then they gave each man a fixed weekly dose of testosterone enanthate for 20 weeks: 25, 50, 125, 300 or 600mg. Energy and protein intake were standardised.

Because endogenous production was shut off, each group sat at a known, stable testosterone concentration. That is what makes this study unusual and why it still has no real successor.

Two things about that table are worth pausing on.

Those concentrations are trough values, measured at the nadir before the next injection, not peaks. So a man on 300mg weekly was sitting at roughly 46.7 nmol/L at his lowest point. The nmol/L column is converted from the reported ng/dL figures and is approximate.

And the 25 and 50mg groups did not gain significant fat-free mass. Those two doses roughly replaced what the GnRH agonist had taken away, so the men were near their own baseline rather than above it.

Look at where 300mg sits. It is not a corner. It is a point on a line that keeps going.

One important caveat: there was no resistance training in this protocol. These men were not lifting. That makes the numbers cleaner as a measure of what the hormone does on its own, and it means you cannot read them as "what you would gain training on this dose".

Why the curve never bends

The 2001 paper did something that gets lost when people quote the headline. It related the response to log testosterone concentration rather than to dose, and across the men in the trial fat-free mass tracked log testosterone at r = 0.73.

A log relationship is the mathematical shape of diminishing returns without a stopping point. Each further doubling of concentration buys another increment of muscle, and each doubling costs progressively more milligrams, which is why the dose curve flattens visually while the relationship itself never terminates. There is no dose in the tested range where the line goes horizontal.

This is the distinction the ceiling myth misses. Diminishing returns and a ceiling are not the same thing. One means the next unit buys less. The other means the next unit buys nothing.

Where the returns actually collapse

If you convert the table into marginal return, the practical picture becomes obvious. These figures are my calculation from the published means, not numbers stated in the paper, and the first row assumes the 50mg group sat at zero, which is what "non-significant" implies but is not the same as a measured zero.

The first 125mg a week does most of the work. After that you are paying roughly four times as much hormone for the same kilogram.

Worth noting what this is not saying. Going from 300 to 600mg still returned 2.7kg of fat-free mass over 20 weeks, which is not nothing. The efficiency drops off a cliff; the effect does not.

What if you are running 300mg a week?

This is the number most people land on, so here is what the data actually says about it.

At 300mg weekly you sat at roughly 1,345 ng/dL at trough, which is several times the top of a normal range, and you gained 5.2kg of fat-free mass over 20 weeks without training. You captured about two thirds of the muscle that the 600mg group got, for half the hormone.

If you went to 600mg you would expect roughly another 2.7kg over the same period, and you would also double the input driving haemoglobin up and HDL down, because those move on the same curve.

If you dropped to 125mg you would still gain, at 3.4kg, and you would be doing it at a fifth of the hormone load.

None of that tells you what to run. It tells you what you are buying, which is a different and more useful thing.

Benefit and harm sit on the same curve

Here is the part that matters most, and the part the ceiling myth gets backwards.

The 2001 paper fit fat-free mass, muscle volume, leg press strength, leg power, fat mass, haemoglobin, HDL cholesterol and IGF-1 to a single dose-response relationship against log testosterone concentration. One curve. The doses that significantly built muscle were the same doses that significantly raised haemoglobin and significantly lowered HDL.

That is worth sitting with, because the popular version of the ceiling argument claims the opposite: that past some dose the benefits stop while the harms keep climbing, so the trade-off flips. Within the range that was tested, they did not diverge. They moved together.

Some things genuinely did not move. PSA, sexual function, mood and visual-spatial cognition showed no significant change at any dose. Different androgen-dependent processes have different dose-response relationships, and not everything scales.

So what is the honest argument for a dose limit? It is not the shape of the curve. It is that the two sides of it behave differently over time.

Muscle is largely transient. Stop, and most of what the hormone added comes off. Some of the harm is not transient. Coronary plaque accumulates. Suppression of the LH and FSH axis can persist for years after cessation. That asymmetry, not a bend in the curve, is the real case for restraint.

For what the haematological side looks like in practice, see our guides on haemoglobin and haematocrit on TRT and how to lower haematocrit. For the lipid side, cholesterol on steroids covers the HDL collapse in detail.

The haematology follows the same line

Erythropoiesis deserves its own mention because it is the most reliably dose-dependent harm in this population.

A later study using the same graded-dose design found haemoglobin and haematocrit rose linearly with dose in both young and older men, and that the slope was steeper in men over 60. Same pattern as muscle: no threshold below which nothing happens, no ceiling above which it stops.

This is why haematocrit is the marker most likely to force a dose decision for you. It is the one that tends to hit a hard limit before anything else does.

Above 600mg there is no data at all

This is the part that should genuinely give people pause.

The 2001 trial stopped at 600mg. No randomised controlled trial has gone higher. There is no dose-response curve above that point, in either direction. We do not know that the benefit continues and we do not know that it stops.

You will find observational studies of men using far more than 600mg, and they report serious findings: reduced ejection fraction, impaired early relaxation velocity, greater coronary plaque volume, and premature mortality in competitive powerlifting cohorts. Those are real and worth reading.

They are also not studies of testosterone. Nobody running above 600mg is running testosterone alone. Those cohorts used multi-drug stacks including oral compounds, and the findings describe polypharmacy, not a dose of one hormone. Attributing them specifically to testosterone would be the same error as the ceiling myth, just pointed in the other direction.

What the natural limit numbers actually showed

While we are correcting things, the fat-free mass index number gets similar treatment.

The original 1995 study found that all 42 drug-free athletes had a normalised FFMI at or below 25.0, with a mean of 21.8. Users ranged from 25 to 35. That got hardened into "25 is the natural limit", which is more than the data supported: it was an upper bound in one modest sample, not a physiological ceiling, and later reappraisals document naturals above it.

The pattern is the same one running through this whole topic. A specific number from a specific study becomes a hard rule, and the caveats get filed off in the retelling.

What this means for your bloodwork

The practical takeaway is not a dose. It is that the dose you pick is testable.

Because benefit and cost sit on one curve, your bloodwork is the readout for both. On any suppressive dose, the panel worth watching is haematocrit and haemoglobin, a full lipid panel with attention to HDL, total and free testosterone with SHBG to interpret them, estradiol, and LH with FSH if fertility matters to you.

Timing matters as much as the panel. Because the 2001 concentrations were troughs, a trough draw is what compares to them, and it is what a clinician compares to a reference range. Our guide on blood test timing on TRT covers how to schedule that around your injection, and testosterone esters compared explains why the ester changes where your trough sits.

Key takeaways

• There is no anabolic ceiling anywhere in the tested range. Fat-free mass was still climbing at 600mg a week, the highest dose ever studied under controlled conditions.
• Marginal return collapses early. The first 125mg a week bought roughly 4.53kg per 100mg; everything after that bought about 1kg per 100mg.
• Diminishing returns and a ceiling are different things. The response fit a log relationship, which flattens without ever stopping.
• Benefit and harm were fit to the same curve. The doses that built muscle were the doses that raised haemoglobin and lowered HDL.
• The real argument for a dose limit is asymmetry over time, not the shape of the curve. Muscle mostly reverses; plaque and HPTA suppression may not.
• Above 600mg there is no controlled data in either direction, and the observational literature up there describes polypharmacy rather than testosterone.
• The 2001 protocol involved no resistance training, so these are not "training plus testosterone" numbers.

---

References

1. Bhasin, S., Woodhouse, L., Casaburi, R., et al. (2001). Testosterone dose-response relationships in healthy young men. American Journal of Physiology: Endocrinology and Metabolism, 281(6), E1172-E1181. PubMed

2. Bhasin, S., Storer, T. W., Berman, N., et al. (1996). The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine, 335(1), 1-7. PubMed

3. Sinha-Hikim, I., Artaza, J., Woodhouse, L., et al. (2002). Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. American Journal of Physiology: Endocrinology and Metabolism, 283(1), E154-E164. PubMed

4. Coviello, A. D., Kaplan, B., Lakshman, K. M., et al. (2008). Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology and Metabolism, 93(3), 914-919. DOI: 10.1210/jc.2007-1692

5. Baggish, A. L., Weiner, R. B., Kanayama, G., et al. (2017). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation, 135(21), 1991-2002. PubMed

6. Rasmussen, J. J., Selmer, C., Ostergren, P. B., et al. (2016). Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation. PLoS One, 11(8), e0161208. PubMed

7. Parssinen, M., Kujala, U., Vartiainen, E., et al. (2000). Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. International Journal of Sports Medicine, 21(3), 225-227. PubMed

8. Kouri, E. M., Pope, H. G., Katz, D. L., & Oliva, P. (1995). Fat-free mass index in users and nonusers of anabolic-androgenic steroids. Clinical Journal of Sport Medicine, 5(4), 223-228. PubMed